Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus 2 (AAV2) glial cell line-derived […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!